Nicholas Coleman

Nicholas Coleman

Auto-generated profile, based on publicly available information

Nicholas Coleman

Department of Pathology University of Cambridge UK

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2007 in The Journal of Pathology
Verified
Journal Article
Closed access
PDF file
MPM Pett
M Pett
NCN Coleman
N Coleman

15 February 2004 in Cancer Research
Verified
Journal Article
Closed access
PDF file
MPMark R. Pett
Mark R. Pett
WAWilliam O. F. Alazawi
William O. F. Alazawi
IRIan Roberts
Ian Roberts
SDSally Dowen
Sally Dowen
DSDavid I. Smith
David I. Smith
NCNicholas Coleman
Nicholas Coleman
Whereas two key steps in cervical carcinogenesis are integration of high-risk human papillomavirus (HR-HPV) and acquisition of an unstable host genome, the temporal association between these events is poorly understood. Chromosomal instability is induced when HR-HPV E7 oncoprotein is overexpressed from heterologous promoters in vitro. However, it is not known whether such events occur at the “physiologically” elevated levels of E7 produced by deregulation of the homologous HR-HPV promoter after integration. Indeed, an alternative possibility is that integration in vivo is favored in an already unstable host genome. We have addressed these issues using the unique human papillomavirus (HPV) 16-containing cervical keratinocyte cell line W12, which was derived from a low-grade squamous intraepithelial lesion and thus acquired HPV16 by “natural” infection. Whereas W12 at low passage contains HPV16 episomes only, long-term culture results in the emergence of cells containing integrated HPV16 only. We show that integration of HPV16 in W12 is associated with 3′ deletion of the E2 transcriptional repressor, resulting in deregulation of the homologous promoter of the integrant and an increase in E7 protein levels. We further demonstrate that high-level chromosomal instability develops in W12 only after integration and that the forms of instability observed correlate with the physical state of HPV16 DNA and the level of E7 protein. Whereas intermediate E7 levels are associated with numerical chromosomal abnormalities, maximal levels are associated with both numerical and structural aberrations. HR-HPV integration is likely to be a critical event in cervical carcinogenesis, preceding the development of chromosomal abnormalities that drive malignant progression.

30 April 2007 in The Journal of Pathology
Verified
Journal Article
Closed access
PDF file
BMB Muralidhar
B Muralidhar
LGLd Goldstein
Ld Goldstein
GNG Ng
G Ng
DWDm Winder
Dm Winder
RPRd Palmer
Rd Palmer
NCN Coleman
N Coleman

20 January 2015 in The Journal of Pathology
Verified
Journal Article
Closed access
PDF file
IGIan Groves
Ian Groves
NCNicholas Coleman
Nicholas Coleman

15 December 2015 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
MMMatthew J Murray
Matthew J Murray
EBEmma Bell
Emma Bell
KRKatie L Raby
Katie L Raby
MRMartin A Rijlaarsdam
Martin A Rijlaarsdam
AGAd J M Gillis
Ad J M Gillis
NCNicholas Coleman
Nicholas Coleman
The current biomarkers alpha-fetoprotein and human chorionic gonadotropin have limited sensitivity and specificity for diagnosing malignant germ-cell tumours (GCTs). MicroRNAs (miRNAs) from the miR–371–373 and miR–302/367 clusters are overexpressed in all malignant GCTs, and some of these miRNAs show elevated serum levels at diagnosis. Here, we developed a robust technical pipeline to quantify these miRNAs in the serum and cerebrospinal fluid (CSF). The pipeline was used in samples from a cohort of exclusively paediatric patients with gonadal and extragonadal malignant GCTs, compared with appropriate tumour and non-tumour control groups. We developed a method for miRNA quantification that enabled sample adequacy assessment and reliable data normalisation. We performed qRT–PCR profiling for miR–371–373 and miR–302/367 cluster miRNAs in a total of 45 serum and CSF samples, obtained from 25 paediatric patients. The exogenous non-human spike-in cel–miR–39–3p and the endogenous housekeeper miR–30b–5p were optimal for obtaining robust serum and CSF qRT–PCR quantification. A four-serum miRNA panel (miR–371a–3p, miR–372–3p, miR–373–3p and miR–367–3p): (i) showed high sensitivity/specificity for diagnosing paediatric extracranial malignant GCT; (ii) allowed early detection of relapse of a testicular mixed malignant GCT; and (iii) distinguished intracranial malignant GCT from intracranial non-GCT tumours at diagnosis, using CSF and serum samples. The pipeline we have developed is robust, scalable and transferable. It potentially promises to improve clinical management of paediatric (and adult) malignant GCTs.

10 January 2005 in The Journal of Pathology
Verified
Journal Article
Closed access
PDF file
KTKiku‐E K Tachibana
Kiku‐E K Tachibana
MGMichael A Gonzalez
Michael A Gonzalez
NCNicholas Coleman
Nicholas Coleman